Krystal Biotech Inc., a gene therapy company developing topical and intradermal “off-the-shelf” treatments for rare dermatological diseases, has been granted Fast Track Designation by the FDA for KB103 for the treatment of dystrophic epidermolysis bullosa (DEB).    KB103 is the first-ever topically-applied herpes simplex virus (HSV-1) based gene therapy engineered to deliver a human collagen protein to patients suffering from DEB.   DEB is a chronic, progressive and inc...